adynovate
takeda new zealand limited - rurioctocog alfa pegol 2000 [iu]; ; - powder for injection with diluent - 2000 iu - active: rurioctocog alfa pegol 2000 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate
takeda new zealand limited - rurioctocog alfa pegol 250 [iu]; ; - powder for injection with diluent - 250 iu - active: rurioctocog alfa pegol 250 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate
takeda new zealand limited - rurioctocog alfa pegol 500 [iu]; ; - powder for injection with diluent - 500 iu - active: rurioctocog alfa pegol 500 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate
takeda new zealand limited - rurioctocog alfa pegol 1500 [iu]; ; - powder for injection with diluent - 1500 iu - active: rurioctocog alfa pegol 1500 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate
takeda new zealand limited - rurioctocog alfa pegol 3000 [iu]; ; - powder for injection with diluent - 3000 iu - active: rurioctocog alfa pegol 3000 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate
takeda new zealand limited - rurioctocog alfa pegol 750 [iu]; ; - powder for injection with diluent - 750 iu - active: rurioctocog alfa pegol 750 [iu] excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis) adynovate is not indicated for the treatment of von willebrand disease.
adynovate 250 iu injection
modern pharmaceutical company belgium - 1 glass vial (5 ml) lyophilized antihemophilic factor (recombinant) pegylated+1 glass vial (5 ml) solvent+1 baxject ii hi-flow needleless transfer device - injection - 250 iu - cardiovascular system-antifibrinolytics , haemostatics, cardiovascular system-antifibrinolytics , haemostatics
adynovate 500 iu injection
modern pharmaceutical company belgium - 1 glass vial (5 ml) lyophilized antihemophilic factor (recombinant) pegylated+1 glass vial (5 ml) solvent+1 baxject ii hi-flow needleless transfer device - injection - 500 iu - cardiovascular system-antifibrinolytics , haemostatics, cardiovascular system-antifibrinolytics , haemostatics
adynovate 1000 iu injection
modern pharmaceutical company belgium - 1 glass vial (5 ml) lyophilized antihemophilic factor (recombinant) pegylated+1 glass vial (5 ml) solvent+1 baxject ii hi-flow needleless transfer device - injection - 1000 iu - cardiovascular system-antifibrinolytics , haemostatics, cardiovascular system-antifibrinolytics , haemostatics
feiba 500 u 500 u / vial injection
modern pharmaceutical company austria - 1 glass vial powder + 1 vial with 20ml solvent + 1 baxject ii hi-flow + 1 kit - injection - 500 u / vial - cardiovascular system-antifibrinolytics , haemostatics